Neu Health Secures $2 Million Investment from Cedars-Sinai and Oxford Science Enterprises to Revolutionise Neurology Care
Neu Health, a pioneering neurology health-tech company spin-out from the University of Oxford, has secured $2 million in co-investment from Cedars-Sinai and Oxford Science Enterprises (OSE). This funding marks the launch of a groundbreaking partnership between the two organizations to co-build and co-invest in health-tech startups, accelerating their growth in the U.S. and U.K. markets.
The investment will support Neu Health’s expansion into the U.S., starting with a six-month pilot program at Cedars-Sinai. This milestone enables Neu Health to bring its innovative platform, designed for Parkinson’s disease and dementia care, to a broader audience.
Caroline Cake, CEO of Neu Health, shared: “Our goal is to change what’s possible in neurology care. Our partnership with Cedars-Sinai and OSE shows the growing global commitment to improving care for Parkinson’s disease and dementia. Together, we’re building a future where technology helps patients, care givers and doctors manage these challenging conditions.”
Backed by over a decade of Oxford research and clinical validation, Neu Health empowers clinicians, caregivers, and patients alike. The platform’s patient-centric design supports improved symptom monitoring, tailored care plans, and proactive clinical interventions. By integrating patient insights with streamlined clinician workflows, Neu Health is helping preserve independence and enhance the quality of life for those affected by neurodegenerative conditions.
Dr John Glaser, Chairman of the Board at Neu Health, said: Neurological disease has claimed my father and my brother. The Neu Health technology will enable clinicians, patients and family caregivers to take major steps forward in managing these diseases. I am delighted to see the resources and talents of Cedars-Sinai, Oxford Science Enterprises and Neu Health brought to bear to materially advance the management of the health and healthcare of families like mine.
The pilot at Cedars-Sinai will bring Neu Health’s proven approach to 150 patients, paving the way for broader adoption in the U.S. market and strengthening Neu Health’s mission to transform neurology care on a global scale. Neu Health is more than a technology—it’s a movement to ensure every patient, regardless of location, can access the high-quality care they deserve.
About Neu Health
Neu Health is a health-tech company based in London, UK, dedicated to making the latest Parkinson’s disease and dementia care accessible to all. Established in 2022, the company leverages research, data, and clinical validation conducted by neurologists, neuroscientists, and data scientists in the laboratories of Professor Michele Hu and Professor Masud Husain at the University of Oxford. Neu Health’s platform is designed to empower patients, enhance clinician efficiency, and improve outcomes across the care pathway.
Learn more at www.neuhealth.com.
About Oxford Science Enterprises (OSE)
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company created to found, fund, and build transformational businesses through its unique partnership with the University of Oxford. With a focus on Life Sciences, Health Tech, and Deep Tech, OSE has invested over £2.5 billion in groundbreaking companies addressing some of the world’s greatest challenges.
For more information, visit www.oxfordscienceenterprises.com.
About Cedars-Sinai
Cedars-Sinai is a leading nonprofit healthcare organization based in Los Angeles, California, known for its dedication to providing high-quality patient care, innovative research, and advanced medical education. Through strategic initiatives like this partnership, Cedars-Sinai aims to advance patient-centered health-tech solutions and improve healthcare outcomes globally.
Discover more at www.cedars-sinai.org.